Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2‐year double‐blind, placebo‐controlled, randomized trial plus 1‐year open‐label extension

BACKGROUND: Previous clinical trials with birch pollen subcutaneous immunotherapy have been conducted over a 1‐ to 2‐year treatment period and involved mostly a single geographic location. OBJECTIVE: This study (EudraCT‐Number: 2005‐000025‐35) intended to evaluate the effect of subcutaneous immunoth...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Exp Allergy
Hlavní autoři: Worm, Margitta, Rak, Sabina, Samoliński, Boleslaw, Antila, Jukka, Höiby, Ann‐Sofi, Kruse, Brigitte, Lipiec, Agnieszka, Rudert, Michael, Valovirta, Erkka
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
ORIGINAL ARTICLES
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849700/
https://ncbi.nlm.nih.gov/pubmed/30570787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cea.13331
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky